Analyst Sean Lee CFA of H.C. Wainwright maintained a Buy rating on Kazia Therapeutics, with a price target of $13.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Sean Lee CFA has given his Buy rating due to a combination of factors that highlight the promising potential of Kazia Therapeutics’ lead drug candidates. The early results from the Phase 1b study of paxalisib in combination with Keytruda and chemotherapy for metastatic triple-negative breast cancer (TNBC) are encouraging. The significant reduction in circulating tumor cells and clusters in the first patient suggests a synergistic effect that could improve outcomes in TNBC, a cancer type known for poor prognosis.
Additionally, the upcoming clinical milestone for EVT801, Kazia’s VEGFR3 inhibitor, in advanced solid tumors further supports the Buy rating. Previous results indicated that EVT801 was well-tolerated and showed promising responses in high-grade serous ovarian cancer patients. These developments, along with adjustments in the financial model to reflect potential revenues and clinical timelines, have led to the adjustment of the 12-month price target to $13 per ADS, reinforcing the positive outlook for Kazia Therapeutics.